Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Precision BioSciences	Agenus	Athira Pharma	DBV Technologies	Jounce Therapeutics
Symbol	NASDAQ:DTIL	NASDAQ:AGEN	NASDAQ:ATHA	NASDAQ:DBVT	NASDAQ:JNCE
Price Information
Current Price	$8.77	$2.62	$16.59	$6.04	$9.09
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.5	1.6	2.1	1.0	1.6
Analysis Score	3.4	3.5	3.5	2.1	3.3
Community Score	2.8	2.8	3.2	2.4	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.8	3.3	0.0	1.7
Earnings & Valuation Score	0.6	0.6	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$20.00	$8.00	$42.50	$7.25	$15.50
% Upside from Price Target	128.05% upside	205.34% upside	156.18% upside	20.03% upside	70.52% upside
Trade Information
Market Cap	$501.14 million	$536.28 million	$615.82 million	$663.63 million	$412.63 million
Beta	2.08	1.86	N/A	2.91	1.34
Average Volume	1,013,839	3,603,284	397,732	635,016	532,704
Sales & Book Value
Annual Revenue	$22.24 million	$150.05 million	N/A	$14.75 million	$147.87 million
Price / Sales	22.53	3.57	N/A	44.99	2.79
Cashflow	N/A	N/A	N/A	N/A	$2.21 per share
Price / Cash	N/A	N/A	N/A	N/A	4.11
Book Value	$2.72 per share	($1.68) per share	N/A	$2.11 per share	$5.25 per share
Price / Book	3.22	-1.56	N/A	2.86	1.73
Profitability
Net Income	$-92,880,000.00	$-107,660,000.00	$-5,160,000.00	$-172,020,000.00	$56.82 million
EPS	($1.91)	($0.80)	N/A	($2.33)	$1.66
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-484.81%	-192.56%	N/A	N/A	N/A
Return on Equity (ROE)	-105.74%	N/A	N/A	N/A	-72.91%
Return on Assets (ROA)	-53.08%	-97.02%	N/A	N/A	-59.68%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	0.08%	N/A
Current Ratio	2.92%	0.85%	30.75%	4.28%	6.60%
Quick Ratio	2.92%	0.85%	30.75%	4.22%	6.60%
Ownership Information
Institutional Ownership Percentage	48.57%	53.35%	66.68%	32.49%	60.48%
Insider Ownership Percentage	14.30%	4.70%	N/A	15.31%	43.96%
Miscellaneous
Employees	231	359	14	311	128
Shares Outstanding	57.14 million	204.69 million	37.12 million	109.87 million	45.39 million
Next Earnings Date	5/21/2021 (Estimated)	5/6/2021 (Estimated)	6/24/2021 (Estimated)	N/A	5/5/2021 (Estimated)
Optionable	Not Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer finance.yahoo.com - April 12 at 8:23 AM
	Jounce Therapeutics Presents Preclinical Data... benzinga.com - April 11 at 9:03 AM
	Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American ... apnews.com - April 10 at 1:34 PM
	Jounce Therapeutics, Inc. (NASDAQ:JNCE) Insider Sells $136,215.00 in Stock americanbankingnews.com - April 1 at 4:20 PM
	Jounce Therapeutics, Inc. (NASDAQ:JNCE) Receives Consensus Rating of "Hold" from Analysts americanbankingnews.com - April 1 at 6:50 AM
	Jounce Therapeutics, Inc. (NASDAQ:JNCE) Sees Significant Growth in Short Interest americanbankingnews.com - March 30 at 12:18 PM
	Jounce Therapeutics (NASDAQ:JNCE) Stock Price Down 8.7% americanbankingnews.com - March 24 at 2:52 PM
	Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option finance.yahoo.com - March 12 at 12:04 PM
	Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American ... apnews.com - March 11 at 8:54 AM
	Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Virtual (AACR) Annual Meeting finance.yahoo.com - March 10 at 6:30 PM
	Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock finance.yahoo.com - March 10 at 3:27 AM
	Jounce Therapeutics Announces Proposed Offering of Common Stock finance.yahoo.com - March 9 at 5:07 PM
	J.P. Morgan Maintains Their Sell Rating on Jounce Therapeutics (JNCE) smarteranalyst.com - March 5 at 7:45 PM
	Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE) finance.yahoo.com - March 2 at 7:56 AM
	Jounce Therapeutics, Inc. (JNCE) Q4 2020 Earnings Call Transcript finance.yahoo.com - February 26 at 6:03 PM
	Notable Thursday Option Activity: DG, JNCE, AMC nasdaq.com - February 25 at 5:01 PM
	Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - February 25 at 7:00 AM
	Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021 finance.yahoo.com - February 18 at 9:21 AM
	Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors finance.yahoo.com - February 12 at 8:09 AM
	Jounce Therapeutics, Inc. (NASDAQ:JNCE) On Friday – Up 78.84 Percent From Lows, What To Expect Going Ahead? marketingsentinel.com - February 8 at 8:58 AM
	JNCE Feb 2021 15.000 put au.finance.yahoo.com - January 28 at 6:13 PM
	JNCE Feb 2021 10.000 put au.finance.yahoo.com - January 26 at 11:29 PM
	JNCE Feb 2021 15.000 call au.finance.yahoo.com - January 26 at 11:29 PM
	JNCE Feb 2021 10.000 call au.finance.yahoo.com - January 26 at 6:29 PM
	Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 ... apnews.com - January 14 at 4:18 AM

Date	Company	Brokerage	Action
3/18/2021	Precision BioSciences	Jonestrading	Reiterated Rating
1/29/2021	Precision BioSciences	JPMorgan Chase & Co.	Boost Price Target
12/15/2020	Precision BioSciences	HC Wainwright	Reiterated Rating
11/23/2020	Precision BioSciences	Stifel Nicolaus	Boost Price Target
8/17/2020	Precision BioSciences	Barclays	Reiterated Rating
6/8/2020	Precision BioSciences	William Blair	Reiterated Rating
4/2/2020	Precision BioSciences	The Goldman Sachs Group	Downgrade
8/9/2019	Precision BioSciences	BTIG Research	Initiated Coverage
4/22/2019	Precision BioSciences	Jefferies Financial Group	Initiated Coverage
1/15/2021	Agenus	B. Riley	Reiterated Rating
10/13/2020	Athira Pharma	JMP Securities	Initiated Coverage
3/12/2021	DBV Technologies	SVB Leerink	Reiterated Rating
1/22/2021	DBV Technologies	Societe Generale	Downgrade
1/15/2021	DBV Technologies	Citigroup	Boost Price Target
8/5/2020	DBV Technologies	Morgan Stanley	Lower Price Target
8/4/2020	DBV Technologies	Bryan, Garnier & Co	Downgrade
3/20/2020	DBV Technologies	Kepler Capital Markets	Downgrade
10/16/2019	DBV Technologies	Oddo Bhf	Upgrade
3/22/2021	Jounce Therapeutics	Piper Sandler	Initiated Coverage
2/28/2021	Jounce Therapeutics	Robert W. Baird	Reiterated Rating
11/10/2020	Jounce Therapeutics	Roth Capital	Lower Price Target
11/2/2020	Jounce Therapeutics	Raymond James	Downgrade
2/27/2020	Jounce Therapeutics	Cowen	Reiterated Rating

(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources